<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489940</url>
  </required_header>
  <id_info>
    <org_study_id>MS200647_0020</org_study_id>
    <secondary_id>2019-004833-18</secondary_id>
    <nct_id>NCT04489940</nct_id>
  </id_info>
  <brief_title>Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate bintrafusp alfa monotherapy in participants
      with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a
      centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2020</start_date>
  <completion_date type="Anticipated">February 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by an Independent Review Committee</measure>
    <time_frame>From first administration of study intervention up to study end (assessed up to approximately 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by an Independent Review Committee (IRC)</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response of at Least 6 Months Assessed by an Independent Review Committee (IRC)</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by an Independent Review Committee (IRC)</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by the Investigator</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by the Investigator</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate (DRR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator</measure>
    <time_frame>From first documentation of objective response to the date of first documentation of objective progression disease or death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first administration of study intervention to the date of death due to any cause, assessed up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related AEs, Including Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>From first dose to final assessment up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Bintrafusp alfa at the end of Infusion (Ceoi)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Bintrafusp alfa at the end of the Dosing Interval (C trough)</measure>
    <time_frame>Time from first treatment to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Bintrafusp alfa as Measured by Anti-drug Antibodies Concentration</measure>
    <time_frame>Time from first administration of treatment intervention to planned final assessment at approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Bintrafusp alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Participants will receive an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.</description>
    <arm_group_label>Bintrafusp alfa</arm_group_label>
    <other_name>M7824</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study participants have histologically or cytologically confirmed TNBC

          -  Absence of human epidermal growth factor receptor 2 (HER2), estrogen receptor, and
             progesterone receptor expression must be documented (criteria for defining TNBC are
             outlined in the protocol)

          -  Participants must have received at least one line of systemic therapy for metastatic
             disease and have progressed on the line of therapy immediately prior to study entry.
             There is no limit to the number of prior therapies

          -  Participants may prescreen for HMGA2 expression while on preceding treatment, however
             screening should only occur if in the opinion of the Investigator, the participant
             would likely be eligible for study within 6 months

          -  Participants must have measurable disease

          -  Availability of either archival tumor tissue or fresh core or excisional biopsy of a
             tumor lesion (primary or metastatic, excluding bone biopsies) is mandatory to
             determine HMGA2 expression level prior to enrollment

          -  HMGA2 high tumor expression is required and will be determined by a central lab

          -  Participants who have Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1

          -  Participants have a life expectancy greater than or equal to (&gt;=) 12 weeks as judged
             by the Investigator at study start

          -  Participants have adequate hematological, hepatic and renal and coagulation function
             as defined in the protocol

          -  Participants with known Human Immunodeficiency Virus (HIV) infections are in general
             eligible if the criteria as defined in the protocol are met (Food and Drug
             Administration [FDA] Guidance on Cancer Clinical Trial Eligibility, March 2019)

          -  Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections
             are in general eligible if the criteria as defined in the protocol are met (FDA
             Guidance on Cancer Clinical Trial Eligibility, March 2019)

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with active central nervous system (CNS) metastases causing clinical
             symptoms or metastases that require therapeutic intervention are excluded.
             Participants with a history of treated CNS metastases (by surgery or radiation
             therapy) are not eligible unless they have fully recovered from treatment,
             demonstrated no progression for at least 4 weeks, and are not using steroids for at
             least 7 days prior to the start of study intervention

          -  Participants must not have received prior cancer treatment with any other
             immunotherapy or checkpoint inhibitors, or any other immune-modulating monoclonal
             antibody

          -  Participants that received any organ transplantation, including stem-cell
             transplantation, but with the exception of transplants that do not require
             immunosuppression

          -  Participants with significant acute or chronic infections

          -  Participants with active autoimmune disease that might deteriorate when receiving an
             immunostimulatory agent

          -  Participants with clinically significant cardiovascular/cerebrovascular disease
             including: cerebral vascular accident/stroke, myocardial infarction, unstable angina,
             congestive heart failure, or serious cardiac arrhythmia

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>904-953-2865</phone>
      <email>advani.pooja@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Pooja Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center at Alamance Regional - Alamance Regional Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <email>vinay.gudena@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Vinay Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TheOhio State University, Stefanie Spielman Comprehensive Breast Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <email>bhuvaneswari.ramaswamy@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bhuvaneswari Ramaswamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center - Hillman Cancer Center</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>412-647-2371</phone>
      <email>emensle@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Leisha A Emens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel - Geriatrie</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>+3224774111</phone>
      <email>christel.fontaine@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Christel Fontaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>+3216332211</phone>
      <email>kevin.punie@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Kevin Punie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA Ziekenhuizen - Campus Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>+3234433011</phone>
      <email>luc.dirix@gza.be</email>
    </contact>
    <investigator>
      <last_name>Luc D Dirix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+390282244502</phone>
      <email>armando.santoro@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+390226437626</phone>
      <email>bianchini.giampaolo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giampaolo Bianchini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+39257489599</phone>
      <email>marco.colleoni@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Marco Colleoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale - Dipartimento di Senologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+390815903522</phone>
      <email>delauren@unina.it</email>
    </contact>
    <investigator>
      <last_name>Michelino De Laurentiis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOV - Istituto Oncologico Veneto IRCCS - Oncologia Medica 2</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+390498215290</phone>
      <email>pierfranco.conte@ioveneto.it</email>
    </contact>
    <investigator>
      <last_name>Pierfranco Conte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana - U.O. Oncologia II</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+3950992466</phone>
      <email>alfredo.falcone@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Alfredo Falcone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli - UOC Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>+390630151</phone>
      <email>giampaolo.tortora@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Giampaolo Tortora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH of Arkhangelsk region &quot;Arkhangelsk Clinical Oncological Dispensary&quot; - Chemotherapy</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+78182276501</phone>
      <email>sm_nechaev@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Marina N Nechaeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH &quot; Clinical Oncological Dispensary 1&quot; - Location</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+78612337767</phone>
      <email>best.makarova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yulia M Makarova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FSBSI &quot;Russian Oncological Scientific Center n.a. N.N. Blokhin&quot; - Moscow Cancer Research Centre</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+74953242355</phone>
      <email>ganshinainna77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Inna P Ganshina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+73812601724</phone>
      <email>mvdvorkin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail V Dvorkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;ClinicaUZI4D&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+789288284001</phone>
      <email>dashavita@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Daria V Saenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Clinical Research and Practical Center for specialized medical care (oncology)&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+78125966523</phone>
      <email>moiseenkofv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fedor V Moiseyenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tomsk Research Instutite of Oncology - Chemotherapy</name>
      <address>
        <city>Tomsk</city>
        <zip>634028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+73822418086</phone>
      <email>goldbergve@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Viktor E Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>+7347248551800</phone>
      <email>lipatovoleg@bk.ru</email>
    </contact>
    <investigator>
      <last_name>Oleg N Lipatov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia - Dept of Oncology</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <phone>+34957010429</phone>
      <email>juhaba@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Rafael de la Haba Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <phone>+34914269070</phone>
      <email>itacayoli@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yolanda Jerez Gilarranz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <phone>+34913875000</phone>
      <email>jacortes@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Javier Cortes Castan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <phone>+34913368263</phone>
      <email>elemiranda@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Lopez Miranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio - Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <phone>+34955013068</phone>
      <email>ruizsabater@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Ruiz Borrego</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <link>
    <url>http://www.intrapidclinicaltrials.com/en</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M7824</keyword>
  <keyword>INTR@PID</keyword>
  <keyword>Bintrafusp alfa</keyword>
  <keyword>Programmed death-ligand 1</keyword>
  <keyword>Transforming growth factor-β (TGF-β)</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>MS200647</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

